Selank Amidate · Research brief

Semax and Selank Mechanism of Action Compared

Real Peptides Research TeamEditorial

Updated September 30, 20269 min read

56 WORDS

Short answer

Semax and Selank look nearly interchangeable on a spec sheet. Both are heptapeptides, seven amino acids long. Both emerged from the same Russian research programme. Both terminate in the identical three-residue tail, Pro-Gly-Pro. That tail is very nearly the only thing they have in common. Everything upstream of it points at an entirely different receptor system.

Key takeaways

Semax is an ACTH(4-10) analog with the hormonal activity removed, while Selank is an analog of the immune tetrapeptide tuftsin, so the two compounds descend from unrelated parent molecules.
Both peptides are seven residues long and both end in the same Pro-Gly-Pro tail, which slows peptidase degradation and is the sole structural feature they genuinely share.
Selank is not a direct GABA-A agonist; published work describes modulation of receptor subunit expression and protection of endogenous enkephalins, which is an indirect mechanism with a different expected time course.
Semax literature clusters around BDNF and TrkB upregulation and neuroprotection, while Selank literature clusters around anxiolytic-like behaviour and cytokine modulation.
Amidated and free-acid forms of either peptide are not interchangeable inputs, and mixing them across arms of the same study introduces a stability variable that can masquerade as a biological result.
Neither compound holds FDA approval; both are supplied strictly for laboratory research and neither is for human or veterinary consumption.

Everything upstream of it points at an entirely different receptor system. We supply both compounds to research laboratories, and the semax and selank mechanism of action question is the one our team fields more than any other, usually phrased as some version of 'aren't these basically the same molecule?' They aren't. One is built from a pituitary hormone fragment. The other is built from an immune signalling peptide.

What is the semax and selank mechanism of action?

Semax is a synthetic analog of the ACTH(4-10) fragment, and the literature reports activity through melanocortin receptor signalling alongside upregulation of BDNF and its TrkB receptor. Selank is an analog of tuftsin, a four-residue immune peptide, with reported GABA-A receptor modulation and inhibition of enkephalin breakdown. Same stabilising tail, different molecular targets.

The common oversimplification is filing both under 'nootropic peptide' and assuming the gap between them is one of strength. It isn't a potency difference. It's a target difference, and the two were designed from unrelated parent molecules to answer unrelated research questions. This piece covers each signalling pathway in detail, the shared chemistry that keeps both peptides intact long enough to do anything at all, and how the semax and selank mechanism of action determines which compound belongs in which experimental design.

Semax: an ACTH fragment with the hormonal activity engineered out

Semax is the sequence Met-Glu-His-Phe-Pro-Gly-Pro, and the first four residues of that chain are lifted directly from adrenocorticotropic hormone. Specifically, from the 4-10 region of ACTH, the stretch long known to carry the hormone's behavioural and memory-related effects rather than its adrenal ones. Strip the rest of the hormone away and you lose corticotropic activity while keeping the neurotropic signalling. That was the design goal at the Institute of Molecular Genetics of the Russian Academy of Sciences, where the compound originated.

What the published work describes is a neurotrophic profile rather than a receptor-agonist punch. Reports point to increased expression of BDNF (brain-derived neurotrophic factor, the protein that supports neuron survival and synaptic plasticity) and of TrkB, the receptor BDNF binds to. Additional reported activity includes modulation of dopaminergic and serotonergic transmission and inhibition of enzymes that degrade endogenous enkephalins.

That combination is why Semax appears mostly in cerebrovascular, cognition and neuroprotection literature rather than anxiety literature. In Russia it has been registered and used clinically for decades under national approval. It holds no FDA approval and no equivalent status elsewhere, and nothing in this article should be read as suggesting otherwise.

Our team has noticed a recurring pattern in how researchers first encounter this compound: they find the ACTH connection and assume a steroid or stress-axis effect is involved. The whole point of the fragment design is that it isn't.

Selank: a tuftsin analog borrowed from the immune system

Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, and its first four residues are tuftsin, a naturally occurring tetrapeptide released from the heavy chain of immunoglobulin G. Tuftsin's native role is immune: it stimulates phagocyte activity. Selank keeps that four-residue core and attaches the same stabilising tail Semax carries, producing a molecule that shows up in both neuropharmacology and immunomodulation literature.

The reported central mechanism is different in kind from Semax. Published work describes modulation of GABA-A receptor subunit expression, effects on serotonin metabolism, and inhibition of enkephalin-degrading enzymes, which allows endogenous enkephalins to persist longer. On the immune side, reports describe shifts in cytokine expression including interleukin-6 and changes in the Th1/Th2 balance.

Here is where most write-ups get it wrong. Selank is repeatedly described online as a GABA agonist, and it isn't one. Nothing in the literature describes it binding the benzodiazepine site and flipping the channel open. What's reported is modulation of receptor subunit expression plus protection of endogenous signalling peptides, an indirect route. That distinction matters enormously in study design, because it predicts a very different time course and a very different tolerance profile from a direct-acting GABAergic compound, and it's the reason the anxiolytic-like effects described in animal work are characterised as occurring without the sedation signature benzodiazepines produce.

Researchers sourcing the compound for behavioural work can review our Selank liquid spray specifications alongside the batch documentation.

The three amino acids doing the quiet work in both molecules

Neither peptide would function without its C-terminal Pro-Gly-Pro tail, and this is the part almost every comparison skips. Native ACTH(4-10) and native tuftsin are both degraded rapidly by plasma and tissue peptidases. A fragment that disappears before it reaches its target is pharmacologically useless no matter how elegant its receptor affinity looks on paper.

Pro-Gly-Pro is a glyproline motif, and attaching it to the C-terminus sharply slows enzymatic cleavage by making the terminal bond a poor substrate for the exopeptidases that would otherwise chew the chain apart. That's the entire design logic shared by both compounds: take a short bioactive fragment with a known target, bolt on a protective tail, and buy the molecule enough time to signal. Glyprolines have also been described as carrying their own modest neuroprotective and gastroprotective activity in the Russian literature, so the tail isn't purely inert scaffolding.

Amidated variants push the same idea further. C-terminal amidation replaces the terminal carboxyl group with an amide, which removes a negative charge and is generally associated with greater peptidase resistance and altered lipophilicity. That's the structural difference between our standard preparations and the Semax amidate peptide and Selank amidate peptide formats, and it's a variable worth controlling deliberately rather than treating two forms as equivalent inputs.

Across the labs we supply, the most common protocol error we see isn't sequence selection. It's comparing results generated with an amidate form against results generated with a free-acid form and treating the difference as a biological finding.

Semax and Selank Mechanism of Action: Side-by-Side Comparison

The table below maps the structural and pharmacological differences that actually drive experimental choice between the two compounds. Read the final column first if you're designing a study rather than reviewing chemistry.

Attribute	Semax	Selank	Bottom line for research design
Parent molecule	Fragment 4-10 of adrenocorticotropic hormone (ACTH)	Tuftsin, a four-residue peptide released from the IgG heavy chain	The parent determines the receptor family; these two share no ancestry above the C-terminal tail
Sequence	Met-Glu-His-Phe-Pro-Gly-Pro (7 residues)	Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 residues)	Identical length and identical tail, with four completely different N-terminal residues carrying the activity
Primary reported mechanism	Melanocortin-linked neurotrophic signalling with reported upregulation of BDNF and TrkB	Reported modulation of GABA-A receptor subunit expression and inhibition of enkephalin degradation	Neurotrophic versus neuromodulatory; endpoints should be chosen accordingly
Secondary reported activity	Effects on dopaminergic and serotonergic transmission; enkephalinase inhibition	Cytokine modulation including IL-6 and Th1/Th2 balance shifts	Selank carries a genuine immunological arm that Semax does not
Typical literature focus	Cerebrovascular models, cognition, neuroprotection	Anxiolytic-like behavioural models, stress response, immune crosstalk	Searching the wrong literature is the fastest way to waste a research cycle
Regulatory status	Registered for clinical use in Russia; no FDA approval	Registered for clinical use in Russia; no FDA approval	Both are research-use-only compounds outside Russia, full stop

What If: Laboratory Scenarios

What if the two lyophilised vials look completely identical?

They will, and the only reliable identifier is the label plus the certificate of analysis. Both compounds present as white lyophilised powder in similar vial formats, and there is no visual, colour or texture cue that distinguishes a heptapeptide from its near-twin. Any lab handling both should physically separate storage locations and verify against batch documentation before reconstitution, because a mislabelled arm invalidates the entire comparison.

What if a vial was left at room temperature overnight?

Document the excursion, note it in the experimental record, and treat the material as a potential confound rather than assuming it is either fine or ruined. Lyophilised peptides are considerably more tolerant of brief ambient exposure than reconstituted solutions, which is why the standard practice is long-term storage of dry powder at -20°C and refrigeration of reconstituted material at 2-8°C. Degradation of a partially compromised peptide is not visible to the eye and cannot be assessed without analytical testing.

What if a supplier cannot produce a certificate of analysis?

Treat the absence of documentation as disqualifying, not as an inconvenience. Purity, identity confirmation by mass spectrometry, and HPLC results are the only evidence that the sequence in the vial matches the sequence on the label, and for two compounds this structurally similar, that evidence is the experiment's foundation. Our published certificates of analysis exist precisely so batch identity is verifiable before a single reconstitution occurs.

What if published results conflict between two studies on the same peptide?

Check the administration route and the peptide form before concluding the findings disagree. Much of the Russian literature on both compounds uses intranasal delivery in animal models, and comparing those results against parenteral or in vitro work introduces pharmacokinetic differences that have nothing to do with the mechanism under investigation.

The Blunt Truth About Choosing Between Them

Here's the honest answer: there is no meaningful body of head-to-head controlled research comparing Semax and Selank on identical endpoints. Almost every direct comparison circulating online is built from anecdote, forum reports and mechanism-based inference, not from a trial designed to answer the question. That means the semax and selank mechanism of action is currently the only rational basis for selecting one over the other in a study design. Match the compound to the pathway you're interrogating. Choosing on the strength of a comparison that was never actually run is how research budgets get spent on the wrong molecule.

Researchers working through compound selection can review the full mechanism breakdowns on our Semax and Selank reference pages, compare the Semax liquid spray specification against its amidate counterpart, or browse the broader research peptide catalogue. Everything here is educational material about the published literature and laboratory handling, not guidance for use in any living subject; these compounds are research-use-only, are not FDA-approved drugs, and anyone with a question concerning an animal's health should talk to their veterinarian rather than a peptide supplier.

The semax and selank mechanism of action story is ultimately a story about a three-amino-acid tail. Two Russian chemists took two short fragments that the body destroys within minutes, one from a pituitary hormone and one from an antibody, and solved the same stability problem the same way. What that tail protects is where the similarity ends and where the research question begins. Anyone treating the two as interchangeable is reading the tail and ignoring the molecule.

References

Peer-reviewed sources on Selank indexed in PubMed, listed for research context. Real Peptides supplies Selank for laboratory research use only.

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine, 2022. PMID 36322304. doi:10.1007/s10517-022-05624-x
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Current reviews in clinical and experimental pharmacology, 2021. PMID 32621722. doi:10.2174/1574884715666200704152810
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. Bulletin of experimental biology and medicine, 2020. PMID 32651826. doi:10.1007/s10517-020-04868-9
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine, 2019. PMID 31625062. doi:10.1007/s10517-019-04588-9
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bulletin of experimental biology and medicine, 2019. PMID 31243679. doi:10.1007/s10517-019-04512-1
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters, 2018. PMID 30255741. doi:10.2174/0929866525666180925144642
Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bulletin of experimental biology and medicine, 2017. PMID 28853100. doi:10.1007/s10517-017-3817-8

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Semax is a synthetic analog of the ACTH(4-10) hormone fragment and its reported activity centres on melanocortin-linked neurotrophic signalling, including upregulation of BDNF and its TrkB receptor. Selank is an analog of tuftsin, a four-residue immune peptide, with reported GABA-A receptor subunit modulation and inhibition of enkephalin degradation. They share a seven-residue length and an identical Pro-Gly-Pro tail, but the active N-terminal portions come from unrelated parent molecules.

No. The published literature describes Selank as modulating GABA-A receptor subunit expression and protecting endogenous enkephalins from enzymatic breakdown, rather than binding and directly activating the receptor the way a benzodiazepine does. This indirect route is the reason animal studies describe an anxiolytic-like profile without the sedation and tolerance characteristics associated with direct GABAergic agents.

Native ACTH(4-10) and native tuftsin are both broken down rapidly by peptidases, which makes them useless as research tools in their unmodified form. Adding the Pro-Gly-Pro glyproline motif to the C-terminus slows enzymatic cleavage considerably, extending the window in which the molecule can signal. The same stabilising strategy was applied to both compounds independently.

No, and that was the explicit design intent. The 4-10 region of ACTH carries the behavioural and neurotropic activity of the hormone, not the corticotropic activity that stimulates the adrenal cortex. By using only that fragment and adding a stabilising tail, the resulting peptide retains the central signalling profile without the hormone's endocrine action.

Match the compound to the pathway under investigation. Semax literature clusters around neuroprotection, cerebrovascular models and BDNF-related cognitive endpoints, while Selank literature clusters around anxiolytic-like behavioural models, stress response and cytokine modulation. Because no substantial body of head-to-head controlled comparison exists, mechanism is the only defensible selection criterion in a study design.

Neither compound holds FDA approval. Both have been registered and used clinically in Russia for decades under national regulatory frameworks, but outside that jurisdiction they are supplied strictly as research-use-only compounds. They are not for human or veterinary consumption, and no claim of therapeutic benefit is made for them here.

C-terminal amidation replaces the terminal carboxyl group with an amide group, removing a negative charge from the molecule. This change is generally associated with increased resistance to exopeptidase activity and altered lipophilicity. The practical consequence for research is that amidate and free-acid forms should not be treated as interchangeable inputs within the same study.

Standard laboratory practice for lyophilised research peptides is storage of the dry powder at -20°C, with reconstituted material refrigerated at 2-8°C and protected from repeated freeze-thaw cycles. Degradation from temperature excursion is not visually detectable, so any ambient exposure should be documented in the experimental record rather than assumed harmless.

A certificate of analysis documents identity confirmation, typically by mass spectrometry, and purity, typically by HPLC, for the specific batch in hand. Because Semax and Selank are both white lyophilised heptapeptides with no distinguishing visual characteristics, that documentation is the only evidence linking the vial contents to the labelled sequence. Suppliers unable to produce one should be treated as disqualified.

Both peptides were developed within the Russian research system, with the Institute of Molecular Genetics of the Russian Academy of Sciences central to their design, and Selank developed in collaboration with the Zakusov Institute of Pharmacology. The shared origin explains the shared structural strategy of a short bioactive fragment fitted with a protective glyproline tail.

Research literature covering combined administration is limited, and any co-administration design introduces confounds that a single-compound design avoids. Since one compound acts primarily through neurotrophic signalling and the other through receptor modulation and enkephalin protection, attributing an observed effect to either pathway becomes considerably harder when both are present. Isolating mechanisms in separate arms produces cleaner data.

Much of the Russian animal and clinical literature on both peptides used intranasal delivery, which is why comparing those findings against results generated by other routes can produce apparent contradictions that are pharmacokinetic rather than mechanistic. Anyone reviewing conflicting studies should check route and peptide form before concluding the underlying mechanism data disagrees.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA